BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2418 related articles for article (PubMed ID: 10873077)

  • 21. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction.
    Kingston AE; Bergsteinsdottir K; Jessen KR; Van der Meide PH; Colston MJ; Mirsky R
    Eur J Immunol; 1989 Jan; 19(1):177-83. PubMed ID: 2493382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
    Dadmarz RD; Ordoubadi A; Mixon A; Thompson CO; Barracchini KC; Hijazi YM; Steller MA; Rosenberg SA; Schwartzentruber DJ
    Cancer J Sci Am; 1996; 2(5):263-72. PubMed ID: 9166543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic effects of IL-7 and IL-12 on human T cell activation.
    Mehrotra PT; Grant AJ; Siegel JP
    J Immunol; 1995 May; 154(10):5093-102. PubMed ID: 7730615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and local immunosuppression in pancreatic cancer patients.
    von Bernstorff W; Voss M; Freichel S; Schmid A; Vogel I; Jöhnk C; Henne-Bruns D; Kremer B; Kalthoff H
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):925s-932s. PubMed ID: 11300493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma.
    Rousset F; Malefijt RW; Slierendregt B; Aubry JP; Bonnefoy JY; Defrance T; Banchereau J; de Vries JE
    J Immunol; 1988 Apr; 140(8):2625-32. PubMed ID: 2965726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
    Nash MA; Lenzi R; Edwards CL; Kavanagh JJ; Kudelka AP; Verschraegen CF; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 1998 May; 112(2):172-80. PubMed ID: 9649178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
    Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
    Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70.
    Yoshino I; Goedegebuure PS; Peoples GE; Lee KY; Eberlein TJ
    J Immunol; 1994 Nov; 153(9):4149-58. PubMed ID: 7930618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 121.